Pfizer

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
Tuesday, March 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Asahi Kasei Bioprocess’ Massachusetts Training Center Expands 2024 Course Offerings for Career Development and Industry Training

Retrieved on: 
Tuesday, April 2, 2024
Chemicals, Plastics, Alternative Energy, Energy, Manufacturing, Continuing, Pharmaceutical, Education, Training, General Health, Infectious Diseases, Science, Biotechnology, Health, Engineering, Research, AKB, Supervisor, Learning, Pfizer, MTC, Conceptual, Technical, Travel, Student, Multimedia, Tutoring

Asahi Kasei Bioprocess’ (AKB) Massachusetts Training Center has announced an expansion of 2024 class offerings designed for individuals across various stages of their careers.

Key Points: 
  • Asahi Kasei Bioprocess’ (AKB) Massachusetts Training Center has announced an expansion of 2024 class offerings designed for individuals across various stages of their careers.
  • Courses will cover a range of topics, including, but not limited to, bioprocess overview, pathogen safety, and virus removal filter operators' training.
  • View the full release here: https://www.businesswire.com/news/home/20240402865162/en/
    Asahi Kasei Bioprocess' Massachusetts Training Center.
  • In addition, Asahi Kasei is open to feedback to improve the sessions,” said Kyle Eichelmann, Sales Manager at Texcell, when asked about his experience with the MTC program.

BioPhy Appoints Scott Kobayashi as Senior Vice President of Sales to Accelerate Strategic Expansion

Retrieved on: 
Tuesday, April 2, 2024
Health, Technology, Health Technology, General Health, Artificial Intelligence, Pharmaceutical, Biotechnology, Organization, Growth, Pfizer, Fluor, Spark Therapeutics, Patient, AI, EY, Senior, Kobayashi, Clinical trial, Therapy, Drug development, Ecosystem, FDA, Pharmaceutical industry

BioPhy, an innovative AI drug development platform, today announced the appointment of Scott Kobayashi as Senior Vice President of Sales.

Key Points: 
  • BioPhy, an innovative AI drug development platform, today announced the appointment of Scott Kobayashi as Senior Vice President of Sales.
  • In this newly created role, Kobayashi will spearhead BioPhy's expansion in life sciences, public-private healthcare partnerships, financial services, and the public domain.
  • Prior to this, he held pivotal consulting positions at pharmaceutical industry giants Pfizer, Genentech, and Fluor, specializing in business expansion, partnerships, and development strategies.
  • “BioPhy has set itself apart from other biotech solutions with remarkable results in predicting and guiding clinical trial success.

Another Giant Stride: ACCELQ Health & Life Science's Vertical Posts Massive Growth Numbers

Retrieved on: 
Tuesday, April 2, 2024
Apps, Applications, Technology, Security, Software, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Test automation, Automation, SOC, SOC 1, Boston Scientific, Specialization, Pfizer, Name, UnitedHealth Group, Quality, DevOps

The development unfolds after successful implementations of test automation for leading health care enterprises, bringing many business benefits to the table.

Key Points: 
  • The development unfolds after successful implementations of test automation for leading health care enterprises, bringing many business benefits to the table.
  • ACCELQ constantly endeavors to reinvent its AI codeless continuous testing platform making itself agile while aligning itself to various unique business and market demands.
  • This leap into the health care services and life sciences domain comes as no surprise after joining hands with renown names in the industry.
  • ACCELQ has catered to the diverse testing requirements of the application stack of health care behemoths.

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research, Aplastic anemia, Pfizer, AML, Webcast, Patient, Venetoclax, NDA, G&A, Azacitidine, ID, MDS, Bone marrow, RARA, Pharmaceutical industry

Gross proceeds to Syros were approximately $45.0 million, before underwriting discounts and commissions and offering expenses payable by Syros.

Key Points: 
  • Gross proceeds to Syros were approximately $45.0 million, before underwriting discounts and commissions and offering expenses payable by Syros.
  • Cash, cash equivalents and marketable securities as of December 31, 2023, were $139.5 million, as compared with $202.3 million on December 31, 2022.
  • ET to discuss the fourth quarter and full-year 2023 financial results and provide a corporate update.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .

Adobe Summit 2024: Adobe Unveils the Future of Customer Experience Management (CXM) in the Age of Generative AI

Retrieved on: 
Tuesday, March 26, 2024
Technology, Mobile, Wireless, Audio, Video, Apps, Applications, Artificial Intelligence, Other Technology, Software, Digital Marketing, Networks, Communications, Internet, Data Management, Content Marketing, Consumer Electronics, Cloud, CDP, Customer experience, Pfizer, Climate, Social media, Microsoft Azure, Havas, Investment, Asset management, Asset, Media, Marketing, TSB, IPG, General Motors, Publicis, Microsoft Word, Microsoft, Partnership, Workflow, Adobe Experience Cloud, Firefly, AEM, Delta Air Lines, Customer data platform, Data management, Creation, Organization, CXM, Collaboration, Research, OneTrust, Activation, AI, IBM, Imagination, Adobe Creative Cloud, Accenture, B2B, ADBE, Conference, Growth, AJO, Omnicom Group, BigQuery, EY, Life, Google Docs, MLB, Summit, WPP, Multimedia, Sales

In the era of generative AI, Adobe is providing a roadmap to help brands activate AI to deliver customer value and capture the massive opportunity in driving personalization at scale.

Key Points: 
  • In the era of generative AI, Adobe is providing a roadmap to help brands activate AI to deliver customer value and capture the massive opportunity in driving personalization at scale.
  • This is anchored in Adobe Experience Platform, which enables brands to activate customer data across various enterprise systems through an integrated set of applications.
  • Adobe announced today an expanded partnership with Microsoft to deliver generative AI capabilities for marketers that bring powerful Adobe Experience Cloud customer experience insights and Firefly generative AI directly into Microsoft applications to reinvent workflows and ignite productivity.
  • Adobe Summit 2024 is a hybrid event with both an in-person and online presentation powered by Adobe Experience Cloud.

Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Webcast, PFE, Performance report, EDT, Pfizer, Inc.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024.
  • To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada.

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Medication, Astellas Pharma, Pfizer, ALS, Science, Wolfram syndrome, University, FACP, AMX0035, Research, Doctor of Philosophy, MD, Biology, Critical care, Palsy, Drug development, FCCP, Amylyx Pharmaceuticals, Pharmacovigilance, Eli Lilly and Company, CMO, Wolfram, Biotechnology Innovation Organization, Neurodegenerative disease, Medicine, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).
  • Most recently, he served as Chief Medical Officer (“CMO”) of Astellas Pharma, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance.
  • “Dr.
  • Zeiher brings to the Board his distinguished drug development background in overseeing the approval of 15 medicines, and his first-hand experience as a physician.